We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
+74.59%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$667M
AUM Growth
+$150M
Cap. Flow
+$291K
Cap. Flow %
0.04%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$291K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Miscellaneous 4.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$372M 55.73%
4,373,178
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$137M 20.57%
2,111,111
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$109M 16.39%
9,166,667
– –
EPZM
4
CALL
DELISTED
Epizyme, Inc
EPZM
$29.8M 4.47%
2,500,000
– –
CYTK icon
5
Cytokinetics
CYTK
$10.8B
$19M 2.84%
875,656
– –
VIRX
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$16K ﹤0.01%
37,005
+33,305
+900% +$291K

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q3 2020 Portfolio in Review

As of Q3 2020, RP Management held 6 positions worth $667M, up 29% from $517M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2020: portfolio turnover was 0%. RP Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

  • RP Management added most to Viracta Therapeutics, Inc. Common Stock in Q3 2020, an estimated $291K increase.
  • RP Management's ten largest holdings make up 100% of its $667M portfolio in Q3 2020.
  • RP Management opened 0 new positions and closed 0 in Q3 2020.
  • RP Management's portfolio value rose 29% quarter-over-quarter to $667M.

Based on RP Management's 13F filing for Q3 2020, filed 12 Nov 2020.